Strainsforpains, Inc. Sets the Stage for Massive Growth in the Cannabis Industry and AI Innovation
MWN-AI** Summary
Strainsforpains, Inc. (formerly E-Buy Home, Inc., OTC: EBYH) is on track to redefine the wellness, cannabis, and AI integration landscape. Following a successful 2024—where it achieved over $300,000 in CBD sales—the company anticipates exceeding $2 million by the end of 2025, supported by an aggressive expansion of its product lines and geographic footprint. New CBD formulations featuring antioxidants like Australian plum extract are expected to enhance its health and wellness reputation.
Located strategically within Amazon’s expansive AI data center grid in Pennsylvania, Strainsforpains is leveraging its 7-acre facility to forge significant partnerships and technological advancements. The company plans announcements in early 2025 that could redefine its operational capabilities. Additionally, 2025 will see influencer-driven marketing that aims to elevate brand visibility and consumer engagement, alongside a series of media initiatives including a podcast and TV show featuring industry thought leaders.
With over 20 years of research collaborations with prestigious institutions like Harvard and Johns Hopkins, Strainsforpains is pioneering cannabinoid science, supported by an AI-powered app that revolutionizes pain management and patient care. Strategic partnerships, including a joint venture with Cannabis Science, Inc. for cancer treatment advancement, are set to enhance innovation and supply chain resilience.
CEO Y. Simon Shainberg underscores the company's potential at the intersection of wellness and technology, aiming for a NASDAQ uplisting while continuing to build a compelling growth narrative. This forward-looking approach, coupled with robust partnerships and a commitment to AI-driven insights in healthcare, positions Strainsforpains for remarkable future success. Investors should remain vigilant for updates as the company continues to break barriers in the cannabis and technology sectors.
MWN-AI** Analysis
Strainsforpains, Inc. (OTC: EBYH), formerly E-Buy Home, Inc., is strategically positioned to harness significant growth within the burgeoning cannabis and AI markets as it heads into 2025. With reported revenues surpassing $300,000 in 2024 and projected CBD sales reaching $2 million, the company demonstrates robust demand and an expanding product line, targeting health-conscious consumers through innovative formulations featuring antioxidants.
The company’s 7-acre facility in Pennsylvania, nestled within Amazon’s extensive AI data center grid, provides a unique advantage for advancing partnerships and technological capabilities. Investors should closely monitor developments from this strategic site, especially anticipated collaborations that could augment the company’s market presence.
Strainsforpains’ influencer marketing strategy, incorporating endorsements from athletes and celebrities, will enhance brand visibility and drive consumer engagement. This approach aligns well with the industry's trend towards high-profile marketing as a means to establish credibility and attract a diverse customer base.
Moreover, Strainsforpains is at the forefront of cannabinoid science, backed by over two decades of research in partnership with esteemed institutions. Their proprietary AI-powered app, poised to transform pain management and healthcare data access, indicates not just innovation, but potential leadership in data-driven patient care solutions.
Strategic partnerships, including collaborations with Cannabis Science, Inc., and GenBio, enhance Strainsforpains' innovation pipeline and supply chain resilience. These alliances signify the company's commitment to long-term growth and sustainability in a competitive market.
Overall, Strainsforpains, Inc. is a compelling choice for investors seeking exposure to the rapidly expanding intersection of cannabis, AI, and wellness technology. As the company continues to innovate while building its market presence, the potential for substantial returns makes it an appealing prospect in 2025 and beyond. Investors should remain vigilant for forthcoming announcements that may further illuminate the company’s trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH). Strainsforpains, Inc. is redefining the future of wellness, cannabis innovation, and AI integration. With a transformative year in the books, the company is poised to disrupt multiple industries and deliver groundbreaking results in 2025.
Unparalleled Revenue Growth and Market Expansion
"2024 was a milestone year," stated CEO Y. Simon Shainberg. "Our revenues far surpassed expectations, with over $300,000 in CBD sales. Based on current momentum and strong demand, we anticipate exceeding $2 million in CBD sales by the end of 2025."
Strainsforpains is aggressively expanding its product lines and geographic reach, bringing innovative CBD solutions to a wider audience. New formulations featuring powerful antioxidants like Australian plum extract promise to elevate the company’s reputation as a leader in health and wellness solutions.
A Prime Location for Innovation
Strategically positioned within Amazon’s $650 million AI data center grid in Pennsylvania, Strainsforpains' 7-acre facility is a nexus of opportunity. The site’s proximity to one of the largest tech infrastructure projects in the nation opens doors for groundbreaking partnerships and advanced capabilities. Updates on these ventures are expected in Q1 2025, offering investors a glimpse into a high-tech future.
Influencer-Driven Marketing and Endorsements
2025 will see Strainsforpains collaborating with high-profile influencers, athletes, and celebrities to bring its products to the forefront of the market. These partnerships will drive brand visibility, credibility, and consumer engagement across global markets.
Pioneering Cannabis Research and AI Integration
Building on over 20 years of research and collaborations with prestigious institutions such as Harvard, Mt. Sinai, and Johns Hopkins, Strainsforpains is at the forefront of cannabinoid science. The company’s proprietary app, powered by advanced AI algorithms, provides real-time data to healthcare professionals, revolutionizing pain management and patient care.
"We’re blending cutting-edge cannabis research with state-of-the-art AI to improve lives and establish ourselves as leaders in both the medical and tech industries," Shainberg added.
Media and Thought Leadership
Strainsforpains is also making waves in the media with plans for a podcast and TV show in 2025. These platforms will feature expert insights, celebrity endorsements, and compelling stories about the transformative power of cannabis. The podcasts will stream on major platforms like Roku, YouTube, Facebook, and Instagram, amplifying the company’s global reach.
Adding to the momentum, Mr. Shainberg’s upcoming book on cannabis and pain management will debut in February 2025, further cementing Strainsforpains as a thought leader in the wellness industry.
Strategic Partnerships for Long-Term Growth
Our company has several high-impact collaborations that will enhance its overall growth. We have a joint venture with Cannabis Science, Inc. on commercialization and drug development for their Harvard studied and patented cancer killing drugs utilizing cannabinoids. We are proud to have established strong partnerships with Virginia and Pennsylvania farmers and distributors ensuring a resilient and optimized supply chain, with products stored both at our 7-acre Pennsylvania facility and our New York City location. We have a licensing arrangement with GenBio, a biotech research company, whose mission is to develop the next generation of anti-inflammatory drugs. We have a project with Cannasphere Biotech, LLC, an Arizona based leading manufacturer of CBD products, to develop water solubility and nanoliposomal cannabinoid products. All our partnerships and agreements are with companies that have robust proprietary intellectual property, expertise in the cannabis space, and have developed industry relationships. These partnerships enhance its supply chain, innovation pipeline, and market presence.
A Visionary Future
Positioned at the crossroads of wellness and technology, Strainsforpains is set to redefine the cannabis and AI landscapes. With bold plans, strategic alliances, and a relentless commitment to innovation, the company is crafting a compelling growth story that investors won’t want to miss.
Stay tuned for upcoming announcements as Strainsforpains continues to break barriers and shape the future of wellness and data-driven healthcare.
Management and Advisory
Mr. Simon Shainberg has over 17 years of cannabis research and studies within the wellness space, including working with Raphael Mechoulam of Tel Aviv, the well known originator of the concept of the cannabinoid system. He has extensive experience in algorithmic methodology, healthcare technology, pain management, artificial intelligence, and mergers and acquisitions. He is a member of the prestigious International Cannabinoid Research Society, https://icrs.com
Dr. Michael Stern is a board certified urologist and urological surgeon. He served on the faculty at Bast-yr University School of Naturopathic Medicine for 11 years ( 1995-2006). Dr. Stern operated the Northwest healthy Options Clinic in Seattle, Washington. He continues to advise patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including the use of medical cannabis. He is also known for his diet book “The Rotation Diet”.
Mr. Epstein is based in New York City. He is the President and Founder of Geoval Consulting LLC, a firm that applies geological expertise and experience to evaluate prime target investment opportunities. Geoval utilizes geochemical analytical data and modeling for risk profiling to certify geological assets and property selection for private and public entities. He has over 50 publications, including work on experimental and field biogeochemical reactions in saltwater in respected scientific journals, with a focus on successfully merging geology with economic viability. For over 30 years, Samuel Epstein served as an investment advisor as an SVP for Merrill Lynch and Morgan Stanley. For the past 20 years, serves on the Board of Governors for Touro College and University, and acting as an executive director of the Touro College Center for Environmental and Geological Research.
About Strainsforpains, Inc., (OTC: EBYH) fka/ E-Buy Home Inc.
Strainsforpains is progressing towards completing its Audit to become fully-reporting, change its symbol, creating the revenues and asset base for a NASDAQ Uplisting. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. Furthermore, the proprietary app incorporating advanced artificial intelligence, collaborating with pain management departments at hospitals and health care professionals. The app integrates artificial intelligence to expand the selection of cannabis varietals, positioning itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. The company owns a 7 acre facility in Pennsylvania. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/.
Safe Harbor Statement
Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.’s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.
For further info and Media Contact: Y. Simon Shainberg, CEO
1-347-218-0844
simon@strainsforpains.com
https://www.strainsforpains.com/
https://www.facebook.com/profile.php?id=100071016855607
https://twitter.com/strainsforpains https://www.instagram.com/strains_for_pains/
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-apptechnology-and-cbd-market-entrance-with-the-stoc
https://www.youtube.com/watch?v=E-lftNrcFLk
FAQ**
How has the transition from E-Buy Home Inc (EBYH) to Strainsforpains, Inc. impacted investor perception and stock performance?
What specific partnerships with companies like Cannabis Science, Inc. and GenBio can E-Buy Home Inc (EBYH) leverage to enhance its innovation pipeline and revenue growth?
Given Strainsforpains' ambitious sales goals, what are the key strategies to ensure the anticipated growth from E-Buy Home Inc (EBYH) to $2 million in CBD sales by the end of 2025?
How will the upcoming podcast and TV show initiatives contribute to Strainsforpains' brand visibility in connection with its previous identity as E-Buy Home Inc (EBYH)?
**MWN-AI FAQ is based on asking OpenAI questions about E-Buy Home Inc (OTC: EBYH).
NASDAQ: EBYH
EBYH Trading
6.11% G/L:
$0.1703 Last:
1,000 Volume:
$0.1605 Open:
